Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. CDN Services

We are analyzing https://link.springer.com/article/10.1186/s12933-016-0468-4.

Title:
Effect of trelagliptin on vascular endothelial functions and serum adiponectin level in patients with type 2 diabetes: a preliminary single-arm prospective pilot study | Cardiovascular Diabetology
Description:
Trelagliptin, an oral DPP-4 inhibitor, which is administered once per week and characterized by a long half-life in blood. The effects of trelagliptin on vascular endothelial functions have not been clarified to date. The objective of the present study was to examine the effects of trelagliptin on vascular endothelial functions in patients with type 2 diabetes mellitus (DM) using flow-mediated dilatation (FMD), adiponectin, and asymmetric dimethylarginine (ADMA) as evaluation indicators. This study was a preliminary single-arm prospective pilot study. The subjects of this study were type 2 DM patients aged 20–74 years, who visited our outpatient department. The patients were treated with trelagliptin, and their FMD, adiponectin, and ADMA levels were measured at baseline and at 12 weeks after initial treatment to determine the changes during the study period. A total of 27 patients, excluding three dropouts, were included in the population for analysis. Trelagliptin treatment showed no significant changes in FMD (2.42 ± 2.7% at baseline vs. 2.66 ± 3.8% post-treatment, P = 0.785) and ADMA (0.41 ± 0.0 µg/mL at baseline vs. 0.40 ± 0.0 µg/mL post-treatment, P = 0.402). Trelagliptin treatment resulted in a significant increase of serum adiponectin level (7.72 ± 6.9 µg/mL at baseline vs. 8.82 ± 8.3 µg/mL post-treatment, P < 0.002). In this pilot study, trelagliptin treatment showed no significant changes in FMD. On the other hand, it was believed that trelagliptin treatment may increase serum adiponectin level. Trial Registration http://www.umin.ac.jp (Trial ID UMIN000018311)
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

  • Health & Fitness
  • Education
  • Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don't see any clear sign of profit-making.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Link.springer.com could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

study, pubmed, patients, treatment, trelagliptin, article, level, google, scholar, diabetes, adiponectin, type, endothelial, blood, function, fmd, vascular, levels, adma, cas, effects, glucose, baseline, significant, change, central, inhibitor, hbac, cardiovascular, serum, drugs, fasting, bmi, dpp, mellitus, subjects, index, weeks, body, diabetic, pressure, functions, increase, decreased, reported, oral, bapwv, control, mgdl, increased,

Topics {✒️}

endothelial-dependent flow-mediated vasodilation high-density lipoprotein cholesterol article download pdf low-density lipoprotein cholesterol intima-media thickness evaluation physiol endocri-nol metab dipeptidyl peptidase-4 inhibitor parallel-group comparative study long-term extension study β-cell function results full access urinary trace albumin glomerular filtration rate diabetes metab disord /fasting blood glucose fasting blood glucose postprandial endothelial function vascular endothelial functions serum c-peptide level systolic blood pressure ≥160 mmhg left ventricular dysfunction fasting plasma glucose privacy choices/manage cookies vascular endothelial function 0 µg/ml post-treatment 3 µg/ml post-treatment physiol endocrinol metab diastolic blood pressure oral dpp-4 inhibitor nitric oxide synthase diastolic blood pressures lifestyle-related advice creative commons license blood glucose levels diabetes mellitus referred dipeptidyl peptidase-4 flow-mediated dilatation common carotid artery plasma glucose concentration larger sample size dpp-4 inhibitor treatment glucose oxidase method flow-mediated vasodilatation volume pulse waves β-cell function bode-boger sm beta-cell function orally ingest glucose impaired glucose tolerance albumin–creatinine ratio

Questions {❓}

  • Does ADMA cause endothelial dysfunction?
  • The question about smoking status was “Do you currently smoke habitually?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Effect of trelagliptin on vascular endothelial functions and serum adiponectin level in patients with type 2 diabetes: a preliminary single-arm prospective pilot study
         description:Trelagliptin, an oral DPP-4 inhibitor, which is administered once per week and characterized by a long half-life in blood. The effects of trelagliptin on vascular endothelial functions have not been clarified to date. The objective of the present study was to examine the effects of trelagliptin on vascular endothelial functions in patients with type 2 diabetes mellitus (DM) using flow-mediated dilatation (FMD), adiponectin, and asymmetric dimethylarginine (ADMA) as evaluation indicators. This study was a preliminary single-arm prospective pilot study. The subjects of this study were type 2 DM patients aged 20–74 years, who visited our outpatient department. The patients were treated with trelagliptin, and their FMD, adiponectin, and ADMA levels were measured at baseline and at 12 weeks after initial treatment to determine the changes during the study period. A total of 27 patients, excluding three dropouts, were included in the population for analysis. Trelagliptin treatment showed no significant changes in FMD (2.42 ± 2.7% at baseline vs. 2.66 ± 3.8% post-treatment, P = 0.785) and ADMA (0.41 ± 0.0 µg/mL at baseline vs. 0.40 ± 0.0 µg/mL post-treatment, P = 0.402). Trelagliptin treatment resulted in a significant increase of serum adiponectin level (7.72 ± 6.9 µg/mL at baseline vs. 8.82 ± 8.3 µg/mL post-treatment, P < 0.002). In this pilot study, trelagliptin treatment showed no significant changes in FMD. On the other hand, it was believed that trelagliptin treatment may increase serum adiponectin level. Trial Registration http://www.umin.ac.jp (Trial ID UMIN000018311)
         datePublished:2016-11-04T00:00:00Z
         dateModified:2016-11-04T00:00:00Z
         pageStart:1
         pageEnd:9
         license:http://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/s12933-016-0468-4
         keywords:
            Type 2 diabetes mellitus
            Dipeptidyl peptidase-4 inhibitor
            Trelagliptin
            Vascular endothelial functions
            Diabetes
            Angiology
            Cardiology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12933-016-0468-4/MediaObjects/12933_2016_468_Fig1_HTML.gif
         isPartOf:
            name:Cardiovascular Diabetology
            issn:
               1475-2840
            volumeNumber:15
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Satoshi Ida
               affiliation:
                     name:Ise Red Cross Hospital
                     address:
                        name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Kazuya Murata
               affiliation:
                     name:Ise Red Cross Hospital
                     address:
                        name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Katunori Betou
               affiliation:
                     name:Ise Red Cross Hospital
                     address:
                        name:Department of Clinical Laboratory, Ise Red Cross Hospital, Ise-shi, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Chiaki Kobayashi
               affiliation:
                     name:Ise Red Cross Hospital
                     address:
                        name:Department of Clinical Laboratory, Ise Red Cross Hospital, Ise-shi, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yuki Ishihara
               affiliation:
                     name:Ise Red Cross Hospital
                     address:
                        name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kanako Imataka
               affiliation:
                     name:Ise Red Cross Hospital
                     address:
                        name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Akihiro Uchida
               affiliation:
                     name:Ise Red Cross Hospital
                     address:
                        name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kou Monguchi
               affiliation:
                     name:Ise Red Cross Hospital
                     address:
                        name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ryutaro Kaneko
               affiliation:
                     name:Ise Red Cross Hospital
                     address:
                        name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ryoko Fujiwara
               affiliation:
                     name:Ise Red Cross Hospital
                     address:
                        name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Hiroka Takahashi
               affiliation:
                     name:Ise Red Cross Hospital
                     address:
                        name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Effect of trelagliptin on vascular endothelial functions and serum adiponectin level in patients with type 2 diabetes: a preliminary single-arm prospective pilot study
      description:Trelagliptin, an oral DPP-4 inhibitor, which is administered once per week and characterized by a long half-life in blood. The effects of trelagliptin on vascular endothelial functions have not been clarified to date. The objective of the present study was to examine the effects of trelagliptin on vascular endothelial functions in patients with type 2 diabetes mellitus (DM) using flow-mediated dilatation (FMD), adiponectin, and asymmetric dimethylarginine (ADMA) as evaluation indicators. This study was a preliminary single-arm prospective pilot study. The subjects of this study were type 2 DM patients aged 20–74 years, who visited our outpatient department. The patients were treated with trelagliptin, and their FMD, adiponectin, and ADMA levels were measured at baseline and at 12 weeks after initial treatment to determine the changes during the study period. A total of 27 patients, excluding three dropouts, were included in the population for analysis. Trelagliptin treatment showed no significant changes in FMD (2.42 ± 2.7% at baseline vs. 2.66 ± 3.8% post-treatment, P = 0.785) and ADMA (0.41 ± 0.0 µg/mL at baseline vs. 0.40 ± 0.0 µg/mL post-treatment, P = 0.402). Trelagliptin treatment resulted in a significant increase of serum adiponectin level (7.72 ± 6.9 µg/mL at baseline vs. 8.82 ± 8.3 µg/mL post-treatment, P < 0.002). In this pilot study, trelagliptin treatment showed no significant changes in FMD. On the other hand, it was believed that trelagliptin treatment may increase serum adiponectin level. Trial Registration http://www.umin.ac.jp (Trial ID UMIN000018311)
      datePublished:2016-11-04T00:00:00Z
      dateModified:2016-11-04T00:00:00Z
      pageStart:1
      pageEnd:9
      license:http://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/s12933-016-0468-4
      keywords:
         Type 2 diabetes mellitus
         Dipeptidyl peptidase-4 inhibitor
         Trelagliptin
         Vascular endothelial functions
         Diabetes
         Angiology
         Cardiology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12933-016-0468-4/MediaObjects/12933_2016_468_Fig1_HTML.gif
      isPartOf:
         name:Cardiovascular Diabetology
         issn:
            1475-2840
         volumeNumber:15
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Satoshi Ida
            affiliation:
                  name:Ise Red Cross Hospital
                  address:
                     name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Kazuya Murata
            affiliation:
                  name:Ise Red Cross Hospital
                  address:
                     name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Katunori Betou
            affiliation:
                  name:Ise Red Cross Hospital
                  address:
                     name:Department of Clinical Laboratory, Ise Red Cross Hospital, Ise-shi, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Chiaki Kobayashi
            affiliation:
                  name:Ise Red Cross Hospital
                  address:
                     name:Department of Clinical Laboratory, Ise Red Cross Hospital, Ise-shi, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yuki Ishihara
            affiliation:
                  name:Ise Red Cross Hospital
                  address:
                     name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kanako Imataka
            affiliation:
                  name:Ise Red Cross Hospital
                  address:
                     name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Akihiro Uchida
            affiliation:
                  name:Ise Red Cross Hospital
                  address:
                     name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kou Monguchi
            affiliation:
                  name:Ise Red Cross Hospital
                  address:
                     name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ryutaro Kaneko
            affiliation:
                  name:Ise Red Cross Hospital
                  address:
                     name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ryoko Fujiwara
            affiliation:
                  name:Ise Red Cross Hospital
                  address:
                     name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Hiroka Takahashi
            affiliation:
                  name:Ise Red Cross Hospital
                  address:
                     name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Cardiovascular Diabetology
      issn:
         1475-2840
      volumeNumber:15
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Ise Red Cross Hospital
      address:
         name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan
         type:PostalAddress
      name:Ise Red Cross Hospital
      address:
         name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan
         type:PostalAddress
      name:Ise Red Cross Hospital
      address:
         name:Department of Clinical Laboratory, Ise Red Cross Hospital, Ise-shi, Japan
         type:PostalAddress
      name:Ise Red Cross Hospital
      address:
         name:Department of Clinical Laboratory, Ise Red Cross Hospital, Ise-shi, Japan
         type:PostalAddress
      name:Ise Red Cross Hospital
      address:
         name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan
         type:PostalAddress
      name:Ise Red Cross Hospital
      address:
         name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan
         type:PostalAddress
      name:Ise Red Cross Hospital
      address:
         name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan
         type:PostalAddress
      name:Ise Red Cross Hospital
      address:
         name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan
         type:PostalAddress
      name:Ise Red Cross Hospital
      address:
         name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan
         type:PostalAddress
      name:Ise Red Cross Hospital
      address:
         name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan
         type:PostalAddress
      name:Ise Red Cross Hospital
      address:
         name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Satoshi Ida
      affiliation:
            name:Ise Red Cross Hospital
            address:
               name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Kazuya Murata
      affiliation:
            name:Ise Red Cross Hospital
            address:
               name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan
               type:PostalAddress
            type:Organization
      name:Katunori Betou
      affiliation:
            name:Ise Red Cross Hospital
            address:
               name:Department of Clinical Laboratory, Ise Red Cross Hospital, Ise-shi, Japan
               type:PostalAddress
            type:Organization
      name:Chiaki Kobayashi
      affiliation:
            name:Ise Red Cross Hospital
            address:
               name:Department of Clinical Laboratory, Ise Red Cross Hospital, Ise-shi, Japan
               type:PostalAddress
            type:Organization
      name:Yuki Ishihara
      affiliation:
            name:Ise Red Cross Hospital
            address:
               name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan
               type:PostalAddress
            type:Organization
      name:Kanako Imataka
      affiliation:
            name:Ise Red Cross Hospital
            address:
               name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan
               type:PostalAddress
            type:Organization
      name:Akihiro Uchida
      affiliation:
            name:Ise Red Cross Hospital
            address:
               name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan
               type:PostalAddress
            type:Organization
      name:Kou Monguchi
      affiliation:
            name:Ise Red Cross Hospital
            address:
               name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan
               type:PostalAddress
            type:Organization
      name:Ryutaro Kaneko
      affiliation:
            name:Ise Red Cross Hospital
            address:
               name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan
               type:PostalAddress
            type:Organization
      name:Ryoko Fujiwara
      affiliation:
            name:Ise Red Cross Hospital
            address:
               name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan
               type:PostalAddress
            type:Organization
      name:Hiroka Takahashi
      affiliation:
            name:Ise Red Cross Hospital
            address:
               name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan
      name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan
      name:Department of Clinical Laboratory, Ise Red Cross Hospital, Ise-shi, Japan
      name:Department of Clinical Laboratory, Ise Red Cross Hospital, Ise-shi, Japan
      name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan
      name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan
      name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan
      name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan
      name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan
      name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan
      name:Department of Diabetes and Metabolism, Ise Red Cross Hospital, Ise-shi, Japan

External Links {🔗}(184)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Prism.js

CDN Services {📦}

  • Crossref

5s.